Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site (Q33375698)

26 July 2017

title

Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site (English)

1 reference

carcinoma of unknown primary

26 July 2017

main subject

phase II clinical trial

0 references

1 reference

1 reference

1 reference

Gregory P. Kalemkerian

5

object named as

Gregory P Kalemkerian

1 reference

26 July 2017

Bryan J Schneider

1

1 reference

26 July 2017

Basil El-Rayes

2

1 reference

26 July 2017

Jeffery H Muler

3

1 reference

26 July 2017

Philip A Philip

4

1 reference

26 July 2017

Kent A Griffith

6

1 reference

26 July 2017

Mark M Zalupski

7

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

26 July 2017

1 reference

26 July 2017

volume

110

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

770-775

1 reference

26 July 2017

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22857

7 January 2021

Diagnostic and therapeutic management of cancer of an unknown primary

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22857

7 January 2021

Neoplasms of unknown primary site: a clinicopathological study of autopsied patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22857

7 January 2021

Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22857

7 January 2021

Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22857

7 January 2021

Treatment and prognosis of metastatic carcinoma of unknown primary: analysis of 100 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22857

7 January 2021

Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22857

7 January 2021

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22857

7 January 2021

Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22857

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22857

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22857

7 January 2021

Cancer statistics, 1996.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22857

7 January 2021

A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22857

7 January 2021

Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22857

7 January 2021

Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22857

7 January 2021

Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22857

7 January 2021

Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22857

7 January 2021

Prognostic factors in metastatic carcinoma of unknown primary

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22857

7 January 2021

Identifiers

DOI

10.1002/CNCR.22857

1 reference

26 July 2017

1 reference